AI assistant
COGSTATE LTD — Capital/Financing Update 2008
Jul 28, 2008
64644_rns_2008-07-28_12ce6134-b86d-497a-96f2-d28a461e405f.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [235 x 48] intentionally omitted <==
CogState Ltd ABN 80 090 975 723 Level 7 21 Victoria Street Melbourne Vic 3000 Australia
29 July 2008
NOTICE UNDER SECTION 708A(5)(e) OF THE CORPORATIONS ACT 2001 (CTH)
On 28[th] July 2008, CogState Ltd (ABN 80 090 975 723) (ASX:CGS) (Company) issued 7,783,765 fully paid ordinary shares at $0.1027 per share by way of private placement (Issue). The Company relies on section 708A(5) of the Corporations Act 2001 (Cth) (the Act) in relation to the Issue.
In accordance with section 708A(5)(e) of the Act the following information is provided:
-
a) this notice is given within five (5) business days after the day of the Issue;
-
b) the Issue was made without disclosure to investors under Part 6D.2 of the Act;
-
c) this notice is given under section 708A(5)(e) of the Act;
-
d) as at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company and section 674 of the Act;
-
e) as at the date of this notice, there is no excluded information to be provided in accordance with section 708A(6)(e) of the Act.
Questions in respect of this announcement can be directed to CogState CEO, Brad O’Connor, who will be holding a presentation via teleconference today at 12.00 noon AEST.
Dial-in number: 1800 725 725 (Australia only) Passcode: 845 396
If you wish to attend the teleconference from a country other than Australia, please contact Rebecca Piercy on +61 422 916 422 to obtain your toll-free dial-in number.
Lauren Delaney Company Secretary
CogState Ltd ABN 80 090 975 723
==> picture [235 x 48] intentionally omitted <==
Level 7 21 Victoria Street Melbourne Vic 3000 Australia
About CogState:
CogState Ltd (ASX: CGS) specialises in the development and commercialisation of rapid, computerised tests of cognition (brain function). The tests are sold to pharmaceutical, biotechnology, nutraceutical and functional food companies to quantify the effect of drugs or other interventions on human subjects participating in clinical trials.
Since sales into the clinical trials market began in 2004, CogState has secured agreements with organisations including Pfizer, AstraZeneca, GlaxoSmithKline, Merck, Abbott Laboratories, Centres for Disease Control (USA), ALZA Corporation (a member of the Johnson and Johnson group), Lundbeck and Organon USA. CogState is currently expanding its existing activities in the US and European clinical trial markets. For additional information:
Company inquiries: Brad O’Connor Chief Executive Officer CogState Ltd. Ph: 03 9664 1300 Mob: 0411 888 347 [email protected]
Media inquiries: Rebecca Piercy Gavin Anderson & Company Ph: 02 9552 4499 Mob: 0422 916 422 [email protected]